Search results for "ovarian failure"

showing 10 items of 13 documents

The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model.

2021

Abstract STUDY QUESTION Does LH protect mouse oocytes and female fertility from alkylating chemotherapy? SUMMARY ANSWER LH treatment before and during chemotherapy prevents detrimental effects on follicles and reproductive lifespan. WHAT IS KNOWN ALREADY Chemotherapies can damage the ovary, resulting in premature ovarian failure and reduced fertility in cancer survivors. LH was recently suggested to protect prepubertal mouse follicles from chemotoxic effects of cisplatin treatment. STUDY DESIGN, SIZE, DURATION This experimental study investigated LH effects on primordial follicles exposed to chemotherapy. Seven-week-old CD-1 female mice were randomly allocated to four experimental groups: C…

0301 basic medicineLHAlkylating Agentsfertility preservationmedia_common.quotation_subjectDNA repair LH cancer chemotherapy fertility preservation follicle protection ovoprotectionDNA repairOvaryMice SCIDBiologychemotherapyAndrology03 medical and health sciencesMice0302 clinical medicineOvarian FollicleMice Inbred NODPregnancyFollicular phasemedicineAnimalsHumanscancerFertility preservationOvarian follicleOvarian reserveOvarian ReserveOvulationmedia_commonReproductive Biology030219 obstetrics & reproductive medicineRehabilitationObstetrics and GynecologyOriginal ArticlesOocytemedicine.diseaseAcademicSubjects/MED00905Premature ovarian failure030104 developmental biologymedicine.anatomical_structureReproductive Medicinefollicle protectionovoprotectionlipids (amino acids peptides and proteins)FemaleHuman reproduction (Oxford, England)
researchProduct

Children born after autotransplantation of cryopreserved ovarian tissue. a review of 13 live births.

2011

Abstract Introduction. Premature ovarian failure (POF) can occur naturally at an early age or be due to iatrogenic agents. Indeed, ovaries are very sensitive to cytotoxic treatment, especially to radiation and alkylating agents. Methods. Several options are currently available to preserve fertility in cancer patients and allow them to conceive when they have overcome their disease: embryo cryopreservation, oocyte cryopreservation, and ovarian tissue cryopreservation. Cryopreservation of ovarian tissue is the only option available for pre-pubertal girls and women who cannot delay the start of chemotherapy. Findings. Since the first live birth after autotransplantation of cryopreserved ovaria…

Adultmedicine.medical_specialtyendocrine system diseasesOvarian Cortexmedicine.medical_treatmentAntineoplastic AgentsBiologyPrimary Ovarian InsufficiencyTransplantation AutologousCryopreservationYoung AdultEmbryo cryopreservationPregnancyNeoplasmsmedicineHumansOvarian tissue cryopreservationPremature ovarian failureCancerGynecologyCryopreservationTransplantationOvarian cryopreservationOvaryPregnancy OutcomeGeneral MedicineOocyte cryopreservationmedicine.diseasePrognosisfemale genital diseases and pregnancy complicationsAutotransplantationPremature ovarian failureInsufficiencyTransplantationFemaleLive BirthAnnals of medicine
researchProduct

Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy – A technique in its infancy but already successful in fe…

2008

Increasing survival rates in young cancer patients, new reproductive techniques and the growing interest in quality of life after gonadotoxic cancer therapies have placed fertility preservation as an important issue to oncologists, fertility specialists and patients. Several techniques are now available for fertility preservation in these patients. A new promising method is cryopreservation and transplantation of ovarian cortex. Ovarian tissue can be extracted by laparoscopy without any significant delay of gonadotoxic therapy. The tissue can be cryopreserved by specialised centres of reproductive medicine and transplanted in case the women experience premature ovarian failure (POF). This r…

AdultCancer Researchmedicine.medical_specialtyendocrine system diseasesOvarian Cortexmedia_common.quotation_subjectReproductive medicineAntineoplastic AgentsFertilityTissue BanksPrimary Ovarian InsufficiencymedicineHumansOvarian tissue cryopreservationFertility preservationIntensive care medicinemedia_commonCryopreservationOvarian Neoplasmsbusiness.industryOvarymedicine.diseaseSurgeryPremature ovarian failureTransplantationFertilityOncologyTissue bankFemalebusinessEuropean Journal of Cancer
researchProduct

Aging of the musculoskeletal system: How the loss of estrogen impacts muscle strength.

2019

Skeletal muscle weakness occurs with aging and in females this is compounded by the loss of estrogen with ovarian failure. Estrogen deficiency mediates decrements in muscle strength from both inadequate preservation of skeletal muscle mass and decrements in the quality of the remaining skeletal muscle. Processes and components of skeletal muscle that are affected by estrogens are beginning to be identified. This review focuses on mechanisms that contribute to the loss of muscle force generation when estrogen is low in females, and conversely the maintenance of strength by estrogen. Evidence is accumulating that estrogen deficiency induces apoptosis in skeletal muscle contributing to loss of…

estrogeenit0301 basic medicinemedicine.medical_specialtyAgingProteasome Endopeptidase ComplexHistologyPhysiologymedicine.drug_classEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismApoptosisArticle03 medical and health sciences0302 clinical medicineInternal medicineestrogenmedicineHumansMuscle Strengthskeletal muscleta315Muscle SkeletalMuscle forcebusiness.industryagingOvarian failureUbiquitinationSkeletal muscleta3141Estrogensmedicine.diseaseGenerating capacityikääntyminen030104 developmental biologymedicine.anatomical_structureEndocrinologyEstrogenSarcopeniaMuscle strengthEstrogenic EffectsFemalestrengthbusinesshormones hormone substitutes and hormone antagonistslihasvoimaBone
researchProduct

Machine Learning-Based Approach Highlights the Use of a Genomic Variant Profile for Precision Medicine in Ovarian Failure

2021

Ovarian failure (OF) is a common cause of infertility usually diagnosed as idiopathic, with genetic causes accounting for 10–25% of cases. Whole-exome sequencing (WES) may enable identifying contributing genes and variant profiles to stratify the population into subtypes of OF. This study sought to identify a blood-based gene variant profile using accumulation of rare variants to promote precision medicine in fertility preservation programs. A case–control (n = 118, n = 32, respectively) WES study was performed in which only non-synonymous rare variants &lt

0301 basic medicineInfertilityOncologygenomic taxonomymedicine.medical_specialtyprecision medicineovarian failurePopulationMedicine (miscellaneous)BiologyGenoma humàArticlewhole exome sequencing03 medical and health sciences0302 clinical medicineInternal medicinemedicinesingle nucleotide variantFertility preservationeducationGeneExome sequencingeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryRpersonalized medicinePrecision medicinemedicine.diseaseprediction modelMinor allele frequency030104 developmental biologyGinecologiaMedicineovaryPersonalized medicineinfertilitybusinessgenome variant profileJournal of Personalized Medicine
researchProduct

[Contraception in chronically ill adolescents].

2003

Contraception in chronically ill adolescents has to consider side effects with regard to metabolic or hematological disease. Additionally the compliance of the patient has to be taken in account when consulting about contraceptives. In juvenile diabetics with good glycemic control and metabolic diseases of the amino acids oral contraceptives are justifiable. Adolescents with galactose-mia mostly suffer from premature ovarian failure and therefore have to be controlled wether they need contraception at all. Young women with sickle-cell anemia are at risk of thrombophilia. They should not be given hormonal contraceptives. In v. Willebrand-Jurgens-Syndrome oral contraceptives are favourable be…

Malemedicine.medical_specialtyPediatricsAdolescentAnemiaSexual BehaviorDiseaseThrombophiliaDiabetes mellitusmedicineHumansGlycemicGynecologybusiness.industryContraindicationsObstetrics and Gynecologymedicine.diseasePremature ovarian failureChronic diseaseContraceptionDiabetes Mellitus Type 1Sexual behaviorChronic DiseaseFemalebusinessSexualityContraceptives OralZentralblatt fur Gynakologie
researchProduct

Ovarian sex cord tumor with annular tubules in a woman with premature ovarian failure.

2001

Abstract Objective: To report a case of premature ovarian failure (POF) associated with an ovarian sex cord tumor with annular tubules. Design: Case report. Setting: Reproductive endocrinology unit in a tertiary academic center. Patient(s): A 20-year-old woman with POF. Intervention(s): Biopsy of the rudimentary ovary by laparoscopy. Main Outcome Measure(s): Protocol for POF investigation and histological study of the ovarian sample. Result(s): An ovarian sex cord tumor with annular tubules was detected in the rudimentary right ovary. Conclusion(s): The rare ovarian sex cord tumor with annular tubules, which may be hormonally active, was detected in a case of POF.

Adultmedicine.medical_specialtyendocrine system diseasesBiopsyOvaryBiologyPrimary Ovarian InsufficiencyOvarian tumorBiopsymedicineHumansSex Cord-Gonadal Stromal TumorsOvarian follicleLaparoscopyGynecologyOvarian Neoplasmsmedicine.diagnostic_testHistocytochemistryOutcome measuresObstetrics and Gynecologymedicine.diseaseOvarian Sex Cord Tumor with Annular Tubulesfemale genital diseases and pregnancy complicationsPremature ovarian failuremedicine.anatomical_structureReproductive MedicineFemaleFertility and sterility
researchProduct

Re: Infertility Etiologies Are Genetically and Clinically Linked with Other Diseases in Single Meta-Diseases.

2015

The present review aims to ascertain whether different infertility etiologies share particular genes and/or molecular pathways with other pathologies and are associated with distinct and particular risks of later-life morbidity and mortality. In order to reach this aim, we use two different sources of information: (1) a public web server named DiseaseConnect ( http://disease-connect.org ) focused on the analysis of common genes and molecular mechanisms shared by diseases by integrating comprehensive omics and literature data; and (2) a literature search directed to find clinical comorbid relationships of infertility etiologies with only those diseases appearing after infertility is manifest…

InfertilityAdultMalemedicine.medical_specialtyUrologyPopulationReproductive medicineEndometriosisBreast NeoplasmsDiseaseComorbidityBioinformaticsMale infertilityEndocrinologyTesticular NeoplasmsDatabases GeneticmedicineHumansDiseasePhenomicseducationCancerGynecologyeducation.field_of_studyMolecular pathwaysbusiness.industryMental DisordersObstetrics and GynecologyProstatic Neoplasmsmedicine.diseasePolycystic ovaryPremature ovarian failureEditorialReproductive MedicineCardiovascular DiseasesInfertilityEtiologyOsteoporosisFemaleGene expressionbusinessGenital Diseases FemaleDevelopmental BiologyGenome-Wide Association StudyThe Journal of urology
researchProduct

Reproduction beyond cancer: A message of hope for young women

2006

Abstract Objective. Aggressive chemotherapy and radiotherapy or radical oncological surgery in young women with cancer has greatly enhanced these patients' life expectancy, but these treatments often cause infertility or premature ovarian failure due to a massive destruction of the ovarian reserve. The objective of this review is to discuss the effect of the various cancer treatments on fertility and present the various fertility sparing operations and fertility preservation strategies. Method. An extensive survey of the most up-to-date literature was performed. Results. This review discusses the impact of current cancer treatment on fertility potential and the various surgical and assisted…

Infertilitymedicine.medical_specialtyGenital Neoplasms Femalemedia_common.quotation_subjectmedicine.medical_treatmentBreast NeoplasmsFertilitymedicineHumansFertility preservationIntensive care medicineOvarian reservemedia_commonGynecologybusiness.industryObstetrics and GynecologyCancermedicine.diseaseCombined Modality TherapyPremature ovarian failureRadiation therapyFertilityOncologyLife expectancyFemalebusinessInfertility FemaleGynecologic Oncology
researchProduct

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…

2013

PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …

Cancer ResearchTime FactorsLymphomamedicine.medical_treatmentGonadotropin-Releasing Hormone -- agonistsPrimary Ovarian InsufficiencyTriptorelin Pamoate -- therapeutic uselaw.inventionGonadotropin-Releasing HormoneGynécologieRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointBiological Markers -- bloodNorethindrone -- therapeutic useProspective StudiesTreatment FailureProspective cohort studyTriptorelin PamoateEstradiolLymphoma Non-HodgkinLymphoma -- drug therapyMiddle AgedTriptorelinHodgkin DiseasePremature ovarian failureLuteolytic AgentsOncologyHodgkin Disease -- drug therapyDrug Therapy CombinationFemaleEstradiol -- bloodmedicine.drugAdultAntineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effectsmedicine.medical_specialtyNorethisteronemedicine.drug_classUrologyFollicle Stimulating Hormone -- bloodGonadotropin-releasing hormone agonistmedicineHumansGynecologyChemotherapybusiness.industrymedicine.diseaseLuteolytic Agents -- therapeutic useCancérologieLymphoma Non-Hodgkin -- drug therapyPremenopausePrimary Ovarian Insufficiency -- blood -- chemically induced -- prevention & controlFollicle Stimulating HormoneNorethindronebusinessBiomarkersFollow-Up Studies
researchProduct